Kompa AR - Search Results

1

Long-term but not short-term p38 mitogen-activated protein kinase inhibition improves cardiac function and reduces cardiac remodeling post-myocardial infarction.

Kompa AR, See F, Lewis DA, Adrahtas A, Cantwell DM, Wang BH, Krum H. Kompa AR, et al. J Pharmacol Exp Ther. 2008 Jun;325(3):741-50. doi: 10.1124/jpet.107.133546. Epub 2008 Mar 11. J Pharmacol Exp Ther. 2008. PMID: 18334667

2

Regulation of beta-adrenoceptors in a rat model of cardiac failure: effect of perindopril.

Gu XH, Kompa AR, Summers RJ. Gu XH, et al. Among authors: kompa ar. J Cardiovasc Pharmacol. 1998 Jul;32(1):66-74. doi: 10.1097/00005344-199807000-00011. J Cardiovasc Pharmacol. 1998. PMID: 9676723

3

Inotropic responses to human gene 2 (B29) relaxin in a rat model of myocardial infarction (MI): effect of pertussis toxin.

Kompa AR, Samuel CS, Summers RJ. Kompa AR, et al. Br J Pharmacol. 2002 Nov;137(5):710-8. doi: 10.1038/sj.bjp.0704922. Br J Pharmacol. 2002. PMID: 12381685 Free PMC article.

4

Differential effect of urotensin II on vascular tone in normal subjects and patients with chronic heart failure.

Lim M, Honisett S, Sparkes CD, Komesaroff P, Kompa A, Krum H. Lim M, et al. Circulation. 2004 Mar 16;109(10):1212-4. doi: 10.1161/01.CIR.0000121326.69153.98. Epub 2004 Mar 8. Circulation. 2004. PMID: 15007012

5

Cardiovascular role of urotensin II: effect of chronic infusion in the rat.

Kompa AR, Thomas WG, See F, Tzanidis A, Hannan RD, Krum H. Kompa AR, et al. Peptides. 2004 Oct;25(10):1783-8. doi: 10.1016/j.peptides.2004.03.029. Peptides. 2004. PMID: 15476946 Review.

6

p38 mitogen-activated protein kinase inhibition improves cardiac function and attenuates left ventricular remodeling following myocardial infarction in the rat.

See F, Thomas W, Way K, Tzanidis A, Kompa A, Lewis D, Itescu S, Krum H. See F, et al. J Am Coll Cardiol. 2004 Oct 19;44(8):1679-89. doi: 10.1016/j.jacc.2004.07.038. J Am Coll Cardiol. 2004. PMID: 15489104 Free article.

7

Fibrosis as a therapeutic target post-myocardial infarction.

See F, Kompa A, Martin J, Lewis DA, Krum H. See F, et al. Curr Pharm Des. 2005;11(4):477-87. doi: 10.2174/1381612053382098. Curr Pharm Des. 2005. PMID: 15725066 Review.

8

Effect of exogenous urotensin-II on vascular tone in skin microcirculation of patients with essential hypertension.

Sondermeijer B, Kompa A, Komesaroff P, Krum H. Sondermeijer B, et al. Am J Hypertens. 2005 Sep;18(9 Pt 1):1195-9. doi: 10.1016/j.amjhyper.2005.03.748. Am J Hypertens. 2005. PMID: 16182109 Clinical Trial.

9

Effects of a Rho kinase inhibitor on pressure overload induced cardiac hypertrophy and associated diastolic dysfunction.

Phrommintikul A, Tran L, Kompa A, Wang B, Adrahtas A, Cantwell D, Kelly DJ, Krum H. Phrommintikul A, et al. Am J Physiol Heart Circ Physiol. 2008 Apr;294(4):H1804-14. doi: 10.1152/ajpheart.01078.2007. Epub 2008 Feb 1. Am J Physiol Heart Circ Physiol. 2008. PMID: 18245565 Free article.

10

Effect of urotensin II on skin microvessel tone in diabetic patients without heart failure or essential hypertension.

Zomer E, de Ridder I, Kompa A, Komesaroff P, Gilbert R, Krum H. Zomer E, et al. Clin Exp Pharmacol Physiol. 2008 Oct;35(10):1147-50. doi: 10.1111/j.1440-1681.2008.04960.x. Epub 2008 May 23. Clin Exp Pharmacol Physiol. 2008. PMID: 18505448

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

73 results

Search Page

Filters